Clene Inc. (CLNN)
NASDAQ: CLNN · Real-Time Price · USD
5.67
+0.34 (6.38%)
At close: Mar 23, 2026, 4:00 PM EDT
5.78
+0.11 (1.94%)
After-hours: Mar 23, 2026, 5:15 PM EDT
Clene Revenue
In the year 2025, Clene had annual revenue of $200.00K, down -41.52%. Clene had revenue of $77.00K in the quarter ending December 31, 2025, a decrease of -15.38%.
Revenue (ttm)
$200.00K
Revenue Growth
-41.52%
P/S Ratio
339.22
Revenue / Employee
$2,632
Employees
76
Market Cap
66.78M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 200.00K | -142.00K | -41.52% |
| Dec 31, 2024 | 342.00K | -312.00K | -47.71% |
| Dec 31, 2023 | 654.00K | 181.00K | 38.27% |
| Dec 31, 2022 | 473.00K | -250.00K | -34.58% |
| Dec 31, 2021 | 723.00K | 517.00K | 250.97% |
| Dec 31, 2020 | 206.00K | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| The Hain Celestial Group | 1.51B |
| BRC Inc. | 398.26M |
| Bridgford Foods | 233.75M |
| Above Food Ingredients | 213.45M |
| LifeVantage | 210.05M |
| DDC Enterprise | 36.62M |
| BioHarvest Sciences | 32.72M |
| Borealis Foods | 27.90M |
CLNN News
- 11 days ago - Clene Reports Full Year 2025 Financial Results and Recent Operating Highlights - GlobeNewsWire
- 27 days ago - Clene Issues Stockholder Letter Highlighting Upcoming CNM-Au8® 2026 Catalysts - GlobeNewsWire
- 4 weeks ago - Clene to Present at the Emerging Growth Conference - GlobeNewsWire
- 2 months ago - Clene Announces Additional CNM-Au8 Biomarker Data Supporting Potential NDA Filing for Upcoming In-Person FDA Meeting - GlobeNewsWire
- 2 months ago - Clene Announces Registered Direct Offering of Over $28 Million - GlobeNewsWire
- 3 months ago - Clene Announces Statistically Significant ALS Biomarker Results Supporting Accelerated Approval Pathway for CNM-Au8® - GlobeNewsWire
- 3 months ago - Clene to Provide CNM-Au8® ALS Program Update - GlobeNewsWire
- 4 months ago - Clene to Participate at the Benchmark 14th Annual Discovery One-on-One Investor Conference - GlobeNewsWire